"I am impressed with the diverse drug pipeline that Roivant has built in a short period of time, and I admire the company's relentless focus on improving the lives of patients by creating a more efficient drug development model," said Mr. Machado. "I am excited to work with the Roivant team in the years ahead."
About Patrick Machado
Mr. Machado was a co-founder of Medivation, Inc., where he served as Chief Financial Officer for over a decade, from 2004 to 2014. He was also Chief Business Officer at Medivation from 2009 to 2014 and served on its Board of Directors from 2014 to 2016. Mr. Machado also serves on the boards of directors of other biopharmaceutical companies. He graduated from Santa Clara University summa cum laude with a BA in German and a BS in Economics, and received his JD from Harvard Law School.
About Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates with the potential to improve the lives of patients and their families. Roivant's mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the broader healthcare system.
Roivant delivers R&D solutions to its industry partners by helping them unlock value from their pipelines and realize the full potential of their research by completing the product development cycle. Roivant's clinical development pipeline spans multiple therapeutic areas through strategic alliances, collaborations, and partnerships with academic institutions and pharmaceutical companies, including Takeda Pharmaceuticals, Eisai, GlaxoSmithKline, Vertex Pharmaceuticals, Duke University, and Cincinnati Children's Hospital.
Roivant Sciences Ltd. is the majority controlling shareholder of Axovant Sciences Ltd. (NYSE: AXON) and a significant minority shareholder of Arbutus Biopharma Corporation (NASDAQ: ABUS).
For additional information, visit www.roivant.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/patrick-machado-joins-board-of-directors-of-roivant-sciences-300347872.html
SOURCE Roivant Sciences Ltd.